WEBULL
WebtradeDownload

Where Maravai LifeSciences Goes After A 136% Climb

Simply Wall St · 1d ago

Maravai LifeSciences spent this past year talking about GMP enzyme launches, CleanCap contracts and a cost-cutting reset that aimed to repair its financial profile. Holding Maravai LifeSciences over the past year would have returned 136.3%, including dividends. If you had been deciding on 12 November 2025, you would have been weighing that restructuring story against customer concentration and revenue lumpiness. The key consideration is which parts of that mix were solid enough to evaluate before the good news was known.

The useful thing about a Narrative is that the reasoning is checkable: the assumptions sit beside the argument, and together they imply an estimated Fair Value you can disagree with.

This theme extends beyond Maravai LifeSciences. See which of 35 healthcare AI stocks may still merit a closer look.

The Two Maravai LifeSciences Stories Investors Were Arguing Over

The shares cost US$3.25 at the start of the period, so anyone looking at Maravai LifeSciences had to decide which story felt more realistic.

The bullish narrative saw fair value at US$4.12, or 27% above the start price. This view hinged on 2.1% annual revenue growth and a profit margin moving to 14.2% over a three-year window.

The bearish case pointed to fair value of US$2, or 38% below the start price. This view focused on a small 0.1% assumed revenue decline along with pressure from rising regulatory costs and market commoditisation.

NasdaqGS:MRVI 1-Year Stock Price Chart
NasdaqGS:MRVI 1-Year Stock Price Chart

What The Results Changed For The Maravai LifeSciences Debate

Maravai LifeSciences reported Q3 2026 revenue of US$45.85 million and a smaller net loss of US$13.84 million, with net margin improving from a loss of 61.4% to a loss of 30.2%. That shift, along with later quarters that included raised 2026 guidance and positive adjusted EBITDA, supported the optimistic restructuring story, although profitability on a net basis remained unproven.

The lesson is clear. When a turnaround hinges on margin repair, track net margin and guidance revisions together, and test whether rising efficiency is translating into smaller losses or actual earnings elsewhere too.

What Maravai LifeSciences' 136% Run Up Has Not Settled Yet

Maravai LifeSciences trades at US$7.68 after rising 136.3% over the past year. The bullish analyst Narrative on Simply Wall St places its Fair Value above that level, anchored in higher margin products rather than just cost cuts.

The Narrative argues buyers now need to judge whether today’s price fully reflects sustained demand and the mix shift toward TriLink, Cygnus and GMP enzymes.

"The new GMP enzyme manufacturing facility in Jupiter, Florida, including GMP CleanScribe RNA polymerase that can reduce double stranded RNA by up to 85%, gives Maravai LifeSciences Holdings a path to become a single supplier across more of the IVT workflow. This can widen the revenue opportunity per mRNA program and support higher gross margins as volumes build."

One Narrative has put a figure on that disagreement. → See the Narrative with its higher Fair Value, assumptions and all

Which Company Could Surprise You Next?

The story behind this run has already been told. The next one could be taking shape somewhere else. Where could you start looking before it becomes the headline?

  • Company 1 - 45% below our estimate - deploys advanced ATMs and branch automation so higher transaction volumes support efficiency.
  • Company 2 - 34% below our estimate - shifts enterprise clients onto AI centric networking and cloud infrastructure with recurring contracts.
  • Company 3 - 46% below our estimate - uses digital small business platforms to deepen primary banking relationships and stimulate loan demand.

Three companies from the same screener. Open every one of the 32 undervalued companies on it →